1. Cost by Generation First (IVF-ET): for female-factor infertility (tubal, ovulation). 30,000–50,000. Pre-op 3,000–8,000; drugs (domestic 5,000 / imported 20,000) 30%–50%; retrieval+culture+transfer 15,000–25,000; hidden: freezing 1,300/tube/yr, blastocyst 4,000. Second (ICSI): for severe male factor. 50,000–80,000; ICSI +4,000–8,000; micro-TESE 27,000. Third (PGT): for carriers, recurrent loss, advanced age (>38). 80,000–150,000; PGT-A/M 20,000–100,000 (per embryo 3,000–5,000); whole-genome +50,000–80,000; reported clinical pregnancy ~65% after PGT (clinic-reported, not a guarantee), at 3x first-gen cost.

2. Five Variables 1) Physiology: age ≥38 adds 30% drug, +10,000–20,000; severe male factor +27,000; diminished reserve reported >50% single-cycle failure (clinic-reported), multiples raise cost. 2) Drugs/protocol: imported 2–3x domestic; natural cycle saves 15,000 but <10% eligible. 3) Region/tier: tier-1 tertiary 15%–20% above tier-2/3. 4) Add-ons: assisted hatching +5,000; repeat freeze-thaw +2,000–3,000.

3. Ten Centers (2025 single cycle) PKU Third Hospital (Beijing) 35k–60k / 80k–120k; Citic Xiangya (Changsha) 35k–60k / 100k–180k; Shanghai Renji 35k–55k / 120k–150k; Shandong Univ. 35k–50k / 80k–120k; Zhongshan First (Guangzhou) 40k–60k / 90k–150k; West China Second (Chengdu) 35k–55k / ~100k; Nanjing Gulou 35k–60k / 70k–130k; Chongqing Women/Children 35k–50k / 88k–130k; Zhengzhou Univ. First 30k–50k / 40k–70k; Zhejiang Univ. OB/GYN 31k–51k / 70k–140k. (First/second includes drugs, retrieval, transfer, basic culture; third adds genetic testing per embryo 3,000–5,000. Peking Union, Shanghai Ruijin limit daily slots, wider fluctuation.)

4. Cost-Optimization (four steps) 1) Match generation to indication (tubal → first, saves 30k+; Y-microdeletion → third directly). 2) Tiered screening: PGT-A first (20k–30k), then PGT-M. 3) Public tertiary + promo season (15%–20% below private; Sept–Nov discounts, free freezing). 4) Pre-treatment to support single-cycle success: BMI 18.5–24, zinc/selenium (reported ~20% egg-quality support, clinic-reported), micro-stimulation for diminished reserve (30% lower, more cycles).

5. Balance of Cost and Safety 2025 analysis: first = value, second = male-factor, third = genetic risk. Choose a licensed center by medical indication and budget, making every yuan an effective investment in new life. (More info: QR code or 181-0136-5219.)